Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ATRA NASDAQ:FMTX NASDAQ:IMVT NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.61-6.4%$1.39$0.87▼$6.78$160.99M0.74839,202 shs254,301 shsATRAAtara Biotherapeutics$9.23-2.6%$7.94$5.01▼$18.71$55.02M0.18117,330 shs23,402 shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsIMVTImmunovant$18.13+3.6%$15.49$12.72▼$34.47$3.10B0.631.22 million shs1.27 million shsPCVXVaxcyte$35.93-0.9%$33.31$27.66▼$121.06$4.64B1.191.49 million shs1.95 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+9.15%-0.62%+69.47%-67.93%ATRAAtara Biotherapeutics0.00%+15.23%+5.97%+66.91%+2.33%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%IMVTImmunovant0.00%+7.89%+13.74%+23.50%-40.26%PCVXVaxcyte0.00%+8.11%+4.27%+15.16%-55.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.9886 of 5 stars3.12.00.04.53.22.50.0ATRAAtara Biotherapeutics4.5544 of 5 stars3.33.00.04.73.82.50.6FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant1.462 of 5 stars3.40.00.00.02.61.70.0PCVXVaxcyte1.8263 of 5 stars3.61.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00148.45% UpsideATRAAtara Biotherapeutics 2.57Moderate Buy$17.7592.31% UpsideFMTXForma Therapeutics 0.00N/AN/AN/AIMVTImmunovant 2.82Moderate Buy$36.30100.22% UpsidePCVXVaxcyte 3.10Buy$136.50279.91% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ALEC, IMVT, FMTX, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.60N/AN/A$1.29 per share1.25ATRAAtara Biotherapeutics$128.94M0.43N/AN/A($16.89) per share-0.55FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)ATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AIMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)PCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)Latest ATRA, ALEC, IMVT, FMTX, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A8/5/2025Q2 2025PCVXVaxcyte-$1.12N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34ATRAAtara BiotherapeuticsN/A0.570.57FMTXForma TherapeuticsN/A12.7412.74IMVTImmunovantN/A11.1611.16PCVXVaxcyteN/A17.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ATRAAtara Biotherapeutics70.90%FMTXForma Therapeutics87.39%IMVTImmunovant47.08%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%ATRAAtara Biotherapeutics4.00%FMTXForma Therapeutics5.79%IMVTImmunovant5.90%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableIMVTImmunovant120171.07 million160.98 millionOptionablePCVXVaxcyte160129.00 million125.01 millionOptionableATRA, ALEC, IMVT, FMTX, and PCVX HeadlinesRecent News About These CompaniesPrincipal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 11 at 4:01 AM | marketbeat.comBrown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)July 10 at 5:35 AM | marketbeat.comAllspring Global Investments Holdings LLC Lowers Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 4, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average Price Target from AnalystsJuly 3, 2025 | americanbankingnews.comCantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP MeetingJuly 2, 2025 | msn.com86,244 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Peregrine Capital Management LLCJuly 2, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by BrokeragesJune 30, 2025 | marketbeat.comGAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)June 21, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)June 14, 2025 | marketbeat.comVaxcyte: Sentiment Is Pushing The Shares DownJune 10, 2025 | seekingalpha.comHere’s Why Vaxcyte (PCVX) Sold Off in Q1May 27, 2025 | msn.comIs Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?May 9, 2025 | insidermonkey.comVaxcyte Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.comVaxcyte appoints new independent directorMay 3, 2025 | uk.investing.comVaxcyte Appoints Dr. Olivier Brandicourt to BoardMay 1, 2025 | tipranks.comVaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine DevelopmentMay 1, 2025 | quiverquant.comQVaxcyte Appoints Dr. Olivier Brandicourt to Board of DirectorsMay 1, 2025 | globenewswire.comIs Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?April 29, 2025 | insidermonkey.comCommit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using OptionsApril 23, 2025 | nasdaq.comCantor Fitzgerald Initiates Coverage of Vaxcyte (PCVX) with Overweight RecommendationApril 23, 2025 | msn.comTD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)April 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRA, ALEC, IMVT, FMTX, and PCVX Company DescriptionsAlector NASDAQ:ALEC$1.61 -0.11 (-6.40%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.61 0.00 (0.00%) As of 07/11/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Atara Biotherapeutics NASDAQ:ATRA$9.23 -0.25 (-2.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.32 +0.09 (+1.02%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Immunovant NASDAQ:IMVT$18.13 +0.63 (+3.60%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$18.22 +0.09 (+0.50%) As of 07/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Vaxcyte NASDAQ:PCVX$35.93 -0.31 (-0.86%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$35.92 -0.01 (-0.03%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
